New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2013
07:43 EDTRPRXRepros Therapeutics volatility up into positive top-line results for Androxal
Repros Therapeutics overall option implied of 150 is above its 26-week average of 79 according to Track Data, suggesting larger price movement into the reported top-line results for the first pivotal study of Androxal, ZA-301, in the treatment of secondary hypogonadism.
News For RPRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 15, 2015
16:02 EDTRPRXRepros Therapeutics announces Nov. 30, PDUFA goal date for NDA
Subscribe for More Information
April 6, 2015
16:06 EDTRPRXEMA informs Repros that new substance eligible for centralized MAA submission
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use